Everolimus Implicated in Case of Severe Gastrointestinal Hemorrhage
Breast cancer remains the leading cause of cancer and the third leading cause of cancer related deaths among our population with an estimated number of 246,660 new cases and 40,450 deaths in 2016. With treatment advancements, including targeted agents such as Everolimus, a mammalian target of rapamy...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2017/3657812 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562174562664448 |
|---|---|
| author | Paul Gonzales Seth Klusewitz Johanna Marowske John Gancayco Michael B. Osswald Robert Setlik |
| author_facet | Paul Gonzales Seth Klusewitz Johanna Marowske John Gancayco Michael B. Osswald Robert Setlik |
| author_sort | Paul Gonzales |
| collection | DOAJ |
| description | Breast cancer remains the leading cause of cancer and the third leading cause of cancer related deaths among our population with an estimated number of 246,660 new cases and 40,450 deaths in 2016. With treatment advancements, including targeted agents such as Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, survivability and quality of life continue to improve. However, with the use of these agents come adverse effects, some of which are still being characterized. Our case demonstrates recurrent episodes of gastrointestinal bleeding in a 60-year-old woman being treated with Everolimus for progressive metastatic breast cancer. On endoscopy, bleeding was secondary to erosive gastritis. Previous case reports have described bleeding due to gastric antral vascular ectasia (GAVE), which was described in two prior reported cases. In our case, bleeding also occurred on a reduced dose of Everolimus compared to what is previously reported (5 mg versus 10 mg). As a result of her gastrointestinal bleeding, she required multiple endoscopic interventions including argon plasma coagulation and multipolar heater probe to achieve hemostasis. This is the first case reported of gastrointestinal bleeding not consistent with GAVE and occurring while being on a reduced dose of Everolimus. It is important to document our case so that the Gastroenterology and Hematology communities can be educated and made aware for their patient populations on Everolimus. |
| format | Article |
| id | doaj-art-3496a07324164ddb9a312c790bb1dc3d |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-3496a07324164ddb9a312c790bb1dc3d2025-02-03T01:23:16ZengWileyCase Reports in Oncological Medicine2090-67062090-67142017-01-01201710.1155/2017/36578123657812Everolimus Implicated in Case of Severe Gastrointestinal HemorrhagePaul Gonzales0Seth Klusewitz1Johanna Marowske2John Gancayco3Michael B. Osswald4Robert Setlik5Department of Internal Medicine, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, TX 78234, USADepartment of Internal Medicine, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, TX 78234, USAGastroenterology Service, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, TX 78234, USAGastroenterology Service, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, TX 78234, USAHematology/Oncology Service, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, TX 78234, USAHematology/Oncology Service, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, TX 78234, USABreast cancer remains the leading cause of cancer and the third leading cause of cancer related deaths among our population with an estimated number of 246,660 new cases and 40,450 deaths in 2016. With treatment advancements, including targeted agents such as Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, survivability and quality of life continue to improve. However, with the use of these agents come adverse effects, some of which are still being characterized. Our case demonstrates recurrent episodes of gastrointestinal bleeding in a 60-year-old woman being treated with Everolimus for progressive metastatic breast cancer. On endoscopy, bleeding was secondary to erosive gastritis. Previous case reports have described bleeding due to gastric antral vascular ectasia (GAVE), which was described in two prior reported cases. In our case, bleeding also occurred on a reduced dose of Everolimus compared to what is previously reported (5 mg versus 10 mg). As a result of her gastrointestinal bleeding, she required multiple endoscopic interventions including argon plasma coagulation and multipolar heater probe to achieve hemostasis. This is the first case reported of gastrointestinal bleeding not consistent with GAVE and occurring while being on a reduced dose of Everolimus. It is important to document our case so that the Gastroenterology and Hematology communities can be educated and made aware for their patient populations on Everolimus.http://dx.doi.org/10.1155/2017/3657812 |
| spellingShingle | Paul Gonzales Seth Klusewitz Johanna Marowske John Gancayco Michael B. Osswald Robert Setlik Everolimus Implicated in Case of Severe Gastrointestinal Hemorrhage Case Reports in Oncological Medicine |
| title | Everolimus Implicated in Case of Severe Gastrointestinal Hemorrhage |
| title_full | Everolimus Implicated in Case of Severe Gastrointestinal Hemorrhage |
| title_fullStr | Everolimus Implicated in Case of Severe Gastrointestinal Hemorrhage |
| title_full_unstemmed | Everolimus Implicated in Case of Severe Gastrointestinal Hemorrhage |
| title_short | Everolimus Implicated in Case of Severe Gastrointestinal Hemorrhage |
| title_sort | everolimus implicated in case of severe gastrointestinal hemorrhage |
| url | http://dx.doi.org/10.1155/2017/3657812 |
| work_keys_str_mv | AT paulgonzales everolimusimplicatedincaseofseveregastrointestinalhemorrhage AT sethklusewitz everolimusimplicatedincaseofseveregastrointestinalhemorrhage AT johannamarowske everolimusimplicatedincaseofseveregastrointestinalhemorrhage AT johngancayco everolimusimplicatedincaseofseveregastrointestinalhemorrhage AT michaelbosswald everolimusimplicatedincaseofseveregastrointestinalhemorrhage AT robertsetlik everolimusimplicatedincaseofseveregastrointestinalhemorrhage |